<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130911014630N10</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-13</date_registration>
      <primary_sponsor>Vice chancellor for research, Faculty of Pharmacy</primary_sponsor>
      <public_title>Evaluation of Local Effect of Cuttlebone Lipogel on Sub-Cutaneous Fat Accumulation</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of Local Effect of Cuttlebone Lipogel on Sub-Cutaneous Fat Accumulation in women; A Randomized, Placebo-Controlled, Double-Blinded Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-05-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/35383</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Excel software was used for randomization. Using the Rand function in Excel software, random numbers are obtained and using these numbers, each person in the study is placed in drug or placebo group, Blinding description: In this Study,  patients and Data Analyzer have no information about the product that it is drug or placebo. the products have given pre - determined cods and randomly assigned to the patients.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Sub-Cutaneous Fat Accumulation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 15 individual received  Cuttlebone Lipogel. At this stage, based on the recommended amounts of traditional medicine and taking into account the non-toxicity, the amount of Cuttlebone consumption per 100 grams of the gel base is 10 grams and the amount of lipogel consumption three times a day is about 5 grams for an area of 250cm2 (25 × 10 cm) from the person's abdomen will be considered. Duration of the intervention is 12 weeks. Intervention 2: Control group: 15 patients were randomly selected and received placebo for 12 weeks, 3 times a day. 5 grams of the gel applys on 250 cm2 of abdomonal area. The placebo contains all the ingredients of the main medicine, but the active ingredient of the sea floor has been removed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Results from clinical trials

When:
1400/12/10

To whom:
Researchers working in academic institutions

Conditions:
Use of results is allowed only with the mention of the source and In order to expand the study

Where to obtain:
Fatemeh Akbari، 09128518809، f_akbari1987@yahoo.com

How to obtain:
At the request of the researcher, once the medicinal product has been registered, the documents will be sent to the applicant immediately.

Comments:
This plan will be at the disposal of the author for further studies until reaching the pharmaceutical product.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Azadbakht</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>18 KM Kazarabad Road, The Campus of Mazandaran University of Medical Sciences and health services</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>48188-69378</zip>
        <telephone>+98 15 1214 4052</telephone>
        <email>mazadbakht@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Payambar Azam Medicinal Complex-Pharmacy College - Sari</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>-</zip>
        <telephone>+98 912 851 8809</telephone>
        <email>f_akbari1987@Yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>obese women referring to a specialist
Age range 18 to 50 years
patient has a disorder of subcutaneous fat accumulation
patient has a personal dissatisfaction with the use of the product.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>People under 18 and over 50
pregnant women
people with systemic diseases leading to obesity
people taking certain obesity-causing drugs
people who are allergic to plant and seafood products</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 15 individual received  Cuttlebone Lipogel. At this stage, based on the recommended amounts of traditional medicine and taking into account the non-toxicity, the amount of Cuttlebone consumption per 100 grams of the gel base is 10 grams and the amount of lipogel consumption three times a day is about 5 grams for an area of 250cm2 (25 × 10 cm) from the person's abdomen will be considered. Duration of the intervention is 12 weeks.</i_keyword>
      <i_keyword>Control group: 15 patients were randomly selected and received placebo for 12 weeks, 3 times a day. 5 grams of the gel applys on 250 cm2 of abdomonal area. The placebo contains all the ingredients of the main medicine, but the active ingredient of the sea floor has been removed</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Localized obesity or waist size. Timepoint: at baseline and after 12 week. Method of measurement: Tape meters.</prim_outcome>
      <prim_outcome>Waist-Hip Ratio. Timepoint: at baseline and after 12 week. Method of measurement: Tape meters.</prim_outcome>
      <prim_outcome>Blood serum lipid profile including Triglycerides, cholesterol and Low and high density lipoproteins. Timepoint: at baseline and after 12 week. Method of measurement: Blood test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Faculty of Pharmacy</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-06-17</approval_date>
        <contact_name>Ethics Committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Prophet Mohammad Medical Sciences Complex.Farahabad Street Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
